As anticipated, NORAD knockdown and overexpression significantly reduced and enhanced, respectively, CDDP resistance in ESCC cells in vivo, indicating that NORAD might be a novel target for overcoming CDDP resistance in ESCC. Here, NORAD is linked to esophageal squamous cell carcinoma.